Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
Q7Z444

UPID:
RASE_HUMAN

ALTERNATIVE NAMES:
Embryonic stem cell-expressed Ras

ALTERNATIVE UPACC:
Q7Z444

BACKGROUND:
The protein GTPase ERas, with alternative names including Embryonic stem cell-expressed Ras, plays a key role in cell signaling by binding GDP/GTP and showcasing intrinsic GTPase activity. This function is essential for the tumor-like growth properties observed in embryonic stem cells, indicating its importance in cell growth and development.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of GTPase ERas offers a pathway to discovering new therapeutic approaches. Given its critical role in embryonic stem cell proliferation, targeting GTPase ERas could lead to breakthroughs in treating developmental disorders and cancers.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.